Amgen's MariTide and the Push Toward Less Frequent GLP-1 Dosing
Amgen's MariTide is being studied as a monthly injection, aiming to reduce dosing frequency compared with the weekly standard set by Ozempic and Mounjaro.
By the GLP Semaglutide editorial team · Last updated April 22, 2026
Amgen has been developing MariTide, an investigational GLP-1 receptor agonist and GIP receptor antagonist studied with a monthly, rather than weekly, injection schedule, aimed at reducing the dosing burden compared with current market leaders.
A different mechanism than most competitors
MariTide's approach of pairing GLP-1 agonism with GIP receptor antagonism (rather than agonism, as with tirzepatide) reflects an actively debated area of research about which combination of gut hormone receptor activity produces the best efficacy and tolerability profile.
Still investigational
As with any drug in clinical trials, MariTide is not FDA-approved and its eventual label, dosing, and availability — if approved — will depend on completed trial data and regulatory review.
Primary sources